Current Practice: Rationale for Screening Children with Hereditary Hemorrhagic Telangiectasia for Brain Vascular Malformations

References

1. 1.↵
   1. Faughnan ME,
   2. Mager JJ,
   3. Hetts SW, et al

   . Second International Guidelines for The Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. Ann Intern Med 2020;173:989–1001 doi:10.7326/M20-1443 pmid:32894695

   CrossRefPubMed
2. 2.↵
   1. Eker OF,
   2. Boccardi E,
   3. Sure U, et al

   . European Reference Network for Rare Vascular Diseases (VASCERN) position statement on cerebral screening in adults and children with hereditary haemorrhagic telangiectasia (HHT). Orphanet J Rare Dis 2020;15:165 doi:10.1186/s13023-020-01386-9 pmid:32600364

   CrossRefPubMed
3. 3.↵
   1. Dakeishi M,
   2. Shioya T,
   3. Wada Y, et al

   . Genetic epidemiology of hereditary hemorrhagic telangiectasia in a local community in the northern part of Japan. Hum Mutat 2020;19:140–48 doi:10.1002/humu.10026 pmid:11793473

   CrossRefPubMed
4. 4.↵
   1. Govani FS,
   2. Shovlin CL

   . Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur J Hum Genet 2009;17:860–71 doi:10.1038/ejhg.2009.35 pmid:19337313

   CrossRefPubMedWeb of Science
5. 5.↵
   1. McDonald J,
   2. Wooderchak-Donahue W,
   3. VanSant Webb C, et al

   . Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a new era. Front Genet 2015;6:1 doi:10.3389/fgene.2015.00001 pmid:25674101

   CrossRefPubMed
6. 6.↵
   1. Brinjikji W,
   2. Iyer VN,
   3. Wood CP, et al

   . Prevalence and characteristics of brain arteriovenous malformations in hereditary hemorrhagic telangiectasia: a systematic review and meta-analysis. J Neurosurg 2017;127:302–10 doi:10.3171/2016.7.JNS16847 pmid:27767404

   CrossRefPubMed
7. 7.↵
   1. Hetts SW,
   2. Shieh JT,
   3. Ohliger MA, et al

   . Hereditary hemorrhagic telangiectasia: the convergence of genotype, phenotype, and imaging in modern diagnosis and management of a multisystem disease. Radiology 2021;300:17–30 doi:10.1148/radiol.2021203487 pmid:33973836

   CrossRefPubMed
8. 8.↵
   1. Nishida T,
   2. Faughnan ME,
   3. Krings T, et al

   . Brain arteriovenous malformations associated with hereditary hemorrhagic telangiectasia: gene-phenotype correlations. Am J Med Genet A 2012;158A:2829–34 doi:10.1002/ajmg.a.35622 pmid:22991266

   CrossRefPubMed
9. 9.↵
   1. Krings T,
   2. Ozanne A,
   3. Chng SM, et al

   . Neurovascular phenotypes in hereditary haemorrhagic telangiectasia patients according to age: review of 50 consecutive patients aged 1 day–60 years. Neuroradiology 2005;47:711–20 doi:10.1007/s00234-005-1390-8 pmid:16136265

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Krings T,
    2. Kim H,
    3. Power S, et al

    ; Brain Vascular Malformation Consortium HHT Investigator Group. Neurovascular manifestations in hereditary hemorrhagic telangiectasia: imaging features and genotype-phenotype correlations. AJNR Am J Neuroradiol 2015;36:863–70 doi:10.3174/ajnr.A4210 pmid:25572952

    Abstract/FREE Full Text
11. 11.↵
    1. Willemse RB,
    2. Mager JJ,
    3. Westermann CJ, et al

    . Bleeding risk of cerebrovascular malformations in hereditary hemorrhagic telangiectasia. J Neurosurg 2000;92:779–84 doi:10.3171/jns.2000.92.5.0779 pmid:10794291

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Kim H,
    2. Nelson J,
    3. Krings T, et al

    ; Brain Vascular Malformation Consortium HHT Investigator Group. Hemorrhage rates from brain arteriovenous malformation in patients with hereditary hemorrhagic telangiectasia. Stroke 2015;46:1362–64 doi:10.1161/STROKEAHA.114.007367 pmid:25858236

    Abstract/FREE Full Text
13. 13.↵
    1. Bharatha A,
    2. Faughnan ME,
    3. Kim H, et al

    . Brain arteriovenous malformation multiplicity predicts the diagnosis of hereditary hemorrhagic telangiectasia: quantitative assessment. Stroke 2012;43:72–78 doi:10.1161/STROKEAHA.111.629865 pmid:22034007

    Abstract/FREE Full Text
14. 14.↵
    1. Azma R,
    2. Dmytriw AA,
    3. Biswas A, et al

    . Neurovascular manifestations in pediatric patients with hereditary haemorrhagic telangiectasia. Pediatr Neurol 2021;129:24–30 doi:10.1016/j.pediatrneurol.2021.12.004 pmid:35176532

    CrossRefPubMed
15. 15.↵
    1. Ferriero DM,
    2. Fullerton HJ,
    3. Bernard TJ, et al

    ; American Heart Association Stroke Council and Council on Cardiovascular and Stroke Nursing. Management of stroke in neonates and children. Stroke 2019;50:e51–96 doi:10.1161/STR.0000000000000183 pmid:30686119

    CrossRefPubMed
16. 16.↵
    1. Kilian A,
    2. Clancy MS,
    3. Olitsky S, et al

    . Screening for pulmonary and brain vascular malformations is the North American standard of care for patients with hereditary hemorrhagic telangiectasia (HHT): a survey of HHT Centers of Excellence. Vasc Med 2021;26:53–55 doi:10.1177/1358863X20974452 pmid:33375920

    CrossRefPubMed
17. 17.↵
    1. Vella M,
    2. Alexander MD,
    3. Mabray MC, et al

    . Comparison of MRI, MRA, and DSA for detection of cerebral arteriovenous malformations in hereditary hemorrhagic telangiectasia. AJNR Am J Neuroradiol 2020;41:969–75 doi:10.3174/ajnr.A6549 pmid:32381546

    Abstract/FREE Full Text
18. 18.↵
    1. Mohr JP,
    2. Parides MK,
    3. Stapf C, et al

    ; International ARUBA Investigators. Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial. Lancet 2014;383:614–21 doi:10.1016/S0140-6736(13)62302-8 pmid:24268105

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Mohr JP,
    2. Overbey JR,
    3. Hartmann A, et al

    ; ARUBA Co-investigators. Medical management with interventional therapy versus medical management alone for unruptured brain arteriovenous malformations (ARUBA): final follow-up of a multicentre, non-blinded, randomised controlled trial. Lancet Neurol 2020;19:573–81 doi:10.1016/S1474-4422(20)30181-2 pmid:32562682

    CrossRefPubMed
20. 20.↵
    1. Kim H,
    2. Nelson J,
    3. Al-Shahi Salman R, et al

    ; Multicenter Arteriovenous Malformation Rsch (MARS) Investigators. Long-term treatment risk of hemorrhage in unruptured brain arteriovenous malformation patients. Stroke 2023;54:A53 doi:10.1161/str.54.suppl_1.53

    CrossRef
21. 21.↵
    1. White AJ,
    2. Marmor I,
    3. Peacock KM, et al

    . Brain abscess and stroke in children and adults with hereditary hemorrhagic telangiectasia: analysis of a large national claims database. Neurology 2023;100:e2324–30 doi:10.1212/WNL.0000000000207269 pmid:37085327

    CrossRefPubMed
22. 22.↵
    1. Saleh M,
    2. Carter MT,
    3. Latino GA, et al

    . Brain arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia: clinical presentation and anatomical distribution. Pediatr Neurol 2013;49:445–50 doi:10.1016/j.pediatrneurol.2013.07.021 pmid:24080277

    CrossRefPubMed
23. 23.↵
    1. Beslow LA,
    2. Breimann J,
    3. Licht DJ, et al

    . Cerebrovascular malformations in a pediatric hereditary hemorrhagic telangiectasia cohort. Pediatr Neurol 2020;110:49–54 doi:10.1016/j.pediatrneurol.2020.05.008 pmid:32718529

    CrossRefPubMed
24. 24.↵
    1. Kilian A,
    2. Latino GA,
    3. White AJ, et al

    . Comparing characteristics and treatment of brain vascular malformations in children and adults with HHT. J Clin Med 2023;12:2704 doi:10.3390/jcm12072704 pmid:37048789

    CrossRefPubMed
25. 25.↵
    1. Engel ER,
    2. Wusik K,
    3. Bright P, et al

    . Prevalence and predictors of hereditary hemorrhagic telangiectasia and capillary-malformation arteriovenous malformation syndrome among children with neurovascular malformations. J Pediatr 2023;264:113761 doi:10.1016/j.jpeds.2023.113761 pmid:37797790

    CrossRefPubMed
26. 26.↵
    1. Sanchez-Mejia RO,
    2. Chennupati SK,
    3. Gupta N, et al

    . Superior outcomes in children compared with adults after microsurgical resection of brain arteriovenous malformations. J Neurosurg 2006;105:82–87 doi:10.3171/ped.2006.105.2.82 pmid:16922067

    CrossRefPubMed
27. 27.↵
    1. Abla AA,
    2. Nelson J,
    3. Kim H, et al

    . Silent arteriovenous malformation hemorrhage and the recognition of “unruptured” arteriovenous malformation patients who benefit from surgical intervention. Neurosurgery 2015;76:592–600; discussion 600 doi:10.1227/NEU.0000000000000686 pmid:25714514

    CrossRefPubMed
28. 28.↵
    1. Luther E,
    2. McCarthy DJ,
    3. Burks J, et al

    . National reduction in cerebral arteriovenous malformation treatment correlated with increased rupture incidence. J Neurointerv Surg 2023;15:735–40 doi:10.1136/jnis-2022-019110 pmid:35902235

    Abstract/FREE Full Text
29. 29.↵
    1. Spetzler RF,
    2. Martin NA

    . A proposed grading system for arteriovenous malformations. J Neurosurg 1986;65:476–83 doi:10.3171/jns.1986.65.4.0476 pmid:3760956

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Lawton MT,
    2. Kim H,
    3. McCulloch CE, et al

    . A supplementary grading scale for selecting patients with brain arteriovenous malformations for surgery. Neurosurgery 2010;66:702–13; discussion 713 doi:10.1227/01.NEU.0000367555.16733.E1 pmid:20190666

    CrossRefPubMedWeb of Science
31. 31.↵
    1. Nisson PL,
    2. Fard SA,
    3. Walter CM, et al

    . A novel proposed grading system for cerebellar arteriovenous malformations. J Neurosurg 2019;132:1105–15 doi:10.3171/2018.12.JNS181677 pmid:30849761

    CrossRefPubMed
32. 32.↵
    1. Meybodi AT,
    2. Kim H,
    3. Nelson J, et al

    ; Brain Vascular Malformation Consortium HHT Investigator Group. Surgical treatment vs nonsurgical treatment for brain arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia: a retrospective multicenter consortium study. Neurosurgery 2018;82:35–47 doi:10.1093/neuros/nyx168 pmid:28973426

    CrossRefPubMed
33. 33.↵
    1. Geirdal AO,
    2. Dheyauldeen S,
    3. Bachmann-Harildstad G, et al

    . Living with hereditary haemorrhagic telangiectasia: coping and psychological distress: a cross-sectional study. Disabil Rehabil 2013;35:206–13 doi:10.3109/09638288.2012.690500 pmid:22671535

    CrossRefPubMed
34. 34.↵
    1. Zarrabeitia R,
    2. Fariñas-Álvarez C,
    3. Santibáñez M, et al

    . Quality of life in patients with hereditary haemorrhagic telangiectasia (HHT). Health Qual Life Outcomes 2017;15:19 doi:10.1186/s12955-017-0586-z pmid:28114930

    CrossRefPubMed
35. 35.↵
    1. Chaturvedi S,
    2. Clancy M,
    3. Schaefer N, et al

    . Depression and post-traumatic stress disorder in individuals with hereditary hemorrhagic telangiectasia: a cross-sectional survey. Thromb Res 2017;153:14–18 doi:10.1016/j.thromres.2017.03.003 pmid:28314138

    CrossRefPubMed
36. 36.↵
    1. Schulte-Uentrop L,
    2. Goepfert MS

    . Anaesthesia or sedation for MRI in children. Curr Opin Anaesthesiol 2010;23:513–17 doi:10.1097/ACO.0b013e32833bb524 pmid:20531170

    CrossRefPubMed
37. 37.↵
    1. Cravero JP,
    2. Beach ML,
    3. Blike GT, et al

    ; Pediatric Sedation Research Consortium. The incidence and nature of adverse events during pediatric sedation/anesthesia with propofol for procedures outside the operating room: a report from the Pediatric Sedation Research Consortium. Anesth Analg 2009;108:795–804 doi:10.1213/ane.0b013e31818fc334 pmid:19224786

    CrossRefPubMedWeb of Science
38. 38.↵
    1. Cosgrove P,
    2. Krauss BS,
    3. Cravero JP, et al

    . Predictors of laryngospasm during 276,832 episodes of pediatric procedural sedation. Ann Emerg Med 2022;80:485–96 doi:10.1016/j.annemergmed.2022.05.002 pmid:35752522

    CrossRefPubMed
39. 39.↵
    1. Lauzier DC,
    2. Osbun JW,
    3. Chatterjee AR, et al

    . Safety of pediatric cerebral angiography. J Neurosurg Pediatr 2021;29:192–99 doi:10.3171/2021.8.PEDS21301 pmid:34740194

    CrossRefPubMed